Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

PHASE3TerminatedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
ALS
Interventions
DRUG

MT-1186

Oral edaravone

DRUG

Placebo

Oral

Trial Locations (37)

9007

Chefarzt Muskelzentrum/ALS Clinic Kantonsspital St.Gallen Muskelzentrum/ALS Clinic, Sankt Gallen

15213

University Of Pittsburgh Medical Center, Pittsburgh

21205

Johns Hopkins University, Baltimore

68506

Neurology Associates, P.C - Lincoln, Lincoln

72758

Woodland Research Northwest, LLC, Rogers

77019

Nerve And Muscle Center Of Texas, Houston

97080

Universitaetsklinikum Wuerzburg, Würzburg

98195

University of Washington Medical Center, Seattle

32610-3633

UF Health Cancer Center/Clinical Trials Office, Gainesville

30317-2819

Emory University - School of Medicine, Atlanta

60611-2605

Northwestern University Feinberg School of Medicine, Chicago

26506-9180

West Virginia University School of Medicine (WVUSoM) - Movement Disorder Clinic, Morgantown

T6G 2B7

University of Alberta - Walter C Mackenzie Health Sciences Centre (WCM), Edmonton

L8P 1H1

Health Science Center Mcmaster University, Hamilton

N6A 5A5

London Health Sciences Centre - University Hospital, London

G1J 1Z4

CHU de Quebec-Hopital-Enfant-Jesus, Québec

465-8620

National Hospital Organization Higashinagoya National Hospital, Nagoya

466-8560

Nagoya University Hospital, Nagoya

260-8712

National Hospital Organization Chibahigashi National Hospital, Chiba

819-8585

Murakami Karindoh Hospital, Fukuoka

960-1295

Fukushima Medical University Hospital, Fukushima

734-8551

Hiroshima University Hospital, Hiroshima

920-0192

National Hospital Organization Iou National Hospital, Kanazawa

761-0793

Kagawa University Hospital, Kita-gun

236-0004

Yokohama City University Hospital, Yokohama

861-1196

National Hospital Organization Kumamoto Saishun Medical Center, Kōshi

616-8255

National Hospital Organization Utano National Hospital, Kyoto

980-8574

Tohoku University Hospital, Sendai

951-8520

Niigata University Medical & Dental Hospital, Niigata

553-0003

Kansai Electric Power Hospital, Osaka

560-8552

National Hospital Organization Osaka Toneyama Medical Center, Toyonaka

420-8688

National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka

183-0042

Tokyo Metropolitan Neurological Hospital, Fuchū

173-8606

Teikyo University Hospital, Itabashi-ku

143-8541

Toho University Omori Medical Center, Ōta-ku

338-8577

Saitama Neuropsychiatric Institute, Saitama

04763

Hanyang University Medical Center, Wangsimni-ro

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma America Inc.

INDUSTRY